Pipeline AIM Biologicals AEZS-150 AEZS-130 (Macimorelin) Macimorelin Dx
AEZS-150 (Delayed Clearance Parathyroid Hormone Fusion Polypeptides DC-PTH)
Treatment of Chronic Hypoparathyroidism
AEZS-150 (DC-PTH) is the active part of the parathyroid hormone, PTH1-34, linked to a modified version of the growth hormone binding protein (GHBP) with the goal of replacing the PTH activity for one week.
We envision self-administered weekly injections of AEZS-150 to maintain normal serum calcium, phosphate levels, and urinary calcium secretion in patients with hypoparathyroidism.
Hypoparathyroidism
-
Progressive metabolic disorder resulting from insufficient secretion of parathyroid hormone
-
Leads to chronic deficiency of calcium in the blood affecting a number of systems including the neuromuscular and cardiovascular
-
Last endocrine disorder where hormone replacement is not standard of care
-
Market opportunity: US: 60,000 and Europe: 70,000¹
-
Expected to be $2.7 billion market by 2028¹
1. DelveInsight 2022 Hypoparathyroidism – Market insight, epidemiology, and market forecast – 2032
60,000
70,000
Demonstrated Preclinical Efficacy In Vivo
-
Cinacalcet administration rapidly induces classical symptoms of hypoparathyroidism, i.e. reduced plasma calcium level for up to 12-24 h
-
Single treatment with 20 nmol/kg DC-PTH (AEZS-150) at t0h normalizes calcium level at 12 h, effect correlates with plasma exposure
-
Six subsequent treatments of 20 nmol/kg PTH 1-34 (t0-5h) provide only limited improvement of calcium levels
-
The plasma DC-PTH level reaches a maximum after 12 h and demonstrates delayed clearance
